Age, median (min-max) |
75 (19-95) |
62 (18-92) |
<
0.001 |
Sex, n (%)
Male
Female
|
53 (50)
53 (50)
|
45 (70.3)
19 (29.7)
|
0.009
|
Duration of hospitalization before COL therapy,
median (min-max)
|
18 (3-101)
|
14.5 (4-52)
|
0.109
|
APACHE II (mean±SD) |
25.17±6.8 |
21.94±7.85 |
0.007 |
Underlying Diseases, n (%)
Chronic Obstructive Pulmonary Disease (COPD)
Diabetes mellitus (DM)
Cardiac failure (CF)
Coronary artery disease (CAD)
Immunosuppression
Solid organ malignancy
|
61 (57.5)
30 (28.3)
24 (22.6)
30 (28.3)
7 (6.6)
3 (2.8)
|
25 (39.1)
14 (21.9)
9 (14.1)
10 (15.6)
7 (10.9)
1 (1.6)
|
0.02
0.354
0.171
0.059
0.319
1.0
|
Initial serum urea (mg/dL) median (min-max) |
46 (16-125) |
39.5 (9-87) |
0.02 |
Initial serum creatinine (mg/dL) median (min-max) |
0.8 (0.34-1.2) |
0.63 (0.3-1.2) |
< 0.001 |
End-treatment serum urea (mg/dL) median (min-max) |
116 (35-295) |
43.5
(8-169) |
< 0.001 |
End-treatment serum creatinine (mg/dL) median (min-max) |
2.46 (0.73-8) |
0.72 (0.21-1.5) |
< 0.001 |
Concomitant nephrotoxic agent use, n (%)
Sulbactam
Vancomycin
NSAID
NSAID+Sulbactam
NSAID+Sulbactam+Amikacin
ACEI+Sulbactam
AG
ACEI+ARB
AMPHOb
Furosemide
|
78 (73.6)
19 (17.9)
14 (13.2)
3 (2.8)
1 (0.94)
2 (1.9)
1 (0.94)
1 (0.94)
3 (2.8)
1 (0.94)
33 (31.1)
|
34 (53.1)
6 (9.4)
8 (12.5)
3 (4.7)
1 (1.6)
1 (1.6)
2 (3.1)
1 (1.6)
2 (3.1)
1 (1.6)
9 (14.1)
|
0.006
0.127
0.894
0.524
0.716
0.876
0.295
0.716
0.912
0.716
0.012
|
Vasopressor agent use, n (%) |
60 (56.6) |
26 (40.6) |
0.043 |
14-day mortality, n (%) |
50 (47.2) |
22 (34.4) |
0.102 |
28-day mortality, n (%) |
37 (34.9) |
18 (28.1) |
0.029 |
Overall mortality, n (%) |
98 (92.5) |
44 (68.8) |
<
0.001 |